

## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
17.0	2025/11/20	58382-00030	Date of first issue: 2015/02/16

## 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Doravirine Formulation

**Supplier's company name, address and phone number**

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.  
Menuuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

## 2. HAZARDS IDENTIFICATION

**GHS classification of chemical product**

|| Not a hazardous substance or mixture according to the Globally Harmonised System (GHS).

**GHS label elements**

|| No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

**Other hazards which do not result in classification**Important symptoms and out- : Dust contact with the eyes can lead to mechanical irritation.  
lines of the emergency as- Contact with dust can cause mechanical irritation or drying of  
sumed the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Cellulose	9004-34-6	$\geq 20$ - $< 30$	
Doravirine	1338225-97-0	$\geq 10$ - $< 20$	
Magnesium stearate	557-04-0	$\geq 1$ - $< 10$	2-611

**Doravirine Formulation**

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

**4. FIRST AID MEASURES**

- |   |  |
|---|--|
| General advice  | : In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled  | : If inhaled, remove to fresh air.<br>Get medical attention if symptoms occur.   |
| In case of skin contact                                     | : Wash with water and soap.<br>Get medical attention if symptoms occur.  |
| In case of eye contact                                      | : If in eyes, rinse well with water.<br>Get medical attention if irritation develops and persists.   |
| If swallowed  | : If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.<br>Rinse mouth thoroughly with water.                                |
| Most important symptoms and effects, both acute and delayed | : Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation.              |
| Protection of first-aiders                                  | : No special precautions are necessary for first aid responders.   |
| Notes to physician  | : Treat symptomatically and supportively.  |

**5. FIREFIGHTING MEASURES**

- |   |   |
|---|---|
| Suitable extinguishing media                  | : Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                | : None known.   |
| Specific hazards during fire-fighting         | : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health.                   |
| Hazardous combustion products                 | : Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )<br>Halogenated compounds<br>Metal oxides  |
| Specific extinguishing methods                | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for firefighters | : Wear self-contained breathing apparatus for firefighting if necessary.<br>Use personal protective equipment.  |

**6. ACCIDENTAL RELEASE MEASURES**

## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

- Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**7. HANDLING AND STORAGE****Handling**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

## Doravirine Formulation

Version 17.0      Revision Date: 2025/11/20      SDS Number: 58382-00030      Date of last issue: 2025/04/14  
 Date of first issue: 2015/02/16

use of administrative controls.

**Storage**

Conditions for safe storage : Keep in properly labelled containers.  
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

Packaging material : Unsuitable material: None known.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Doravirine	1338225-97-0	TWA	500 µg/m <sup>3</sup> (OEB2)	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

# SAFETY DATA SHEET



## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

---

Physical state	:	powder
Colour	:	off-white
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Boiling point, initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Lower explosion limit and upper explosion limit / flammability limit		
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Decomposition temperature	:	No data available
pH	:	No data available
Evaporation rate	:	Not applicable
Auto-ignition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	Not applicable
Density and / or relative density		
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	Not applicable
Explosive properties	:	Not explosive

## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics  
Particle size : No data available

**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Doravirine:**

Acute oral toxicity : LD50 (Rat): > 750 mg/kg  
Remarks: No mortality observed at this dose.

(Rat): Method: Phototoxicity  
Remarks: No evidence of phototoxicity was observed

LD50 (Dog): > 1,000 mg/kg

## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

Remarks: No mortality observed at this dose.

LD50 (Mouse): > 450 mg/kg

Remarks: No mortality observed at this dose.

**Magnesium stearate:**

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Doravirine:**

Remarks : No data available

**Magnesium stearate:**

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Doravirine:**

Remarks : No data available

**Magnesium stearate:**

Species	: Rabbit
Result	: No eye irritation
Remarks	: Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

**Components:****Doravirine:**

Remarks	: No data available
---------	---------------------

**Magnesium stearate:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

**Doravirine:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative

**Magnesium stearate:**

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials  Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473
-----------------------	---

## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
17.0	2025/11/20	58382-00030	2025/04/14
			Date of first issue: 2015/02/16

Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

**Doravirine:**

Species	: Mouse
Application Route	: Oral
Exposure time	: 6 Months
Result	: negative
Remarks	: No significant adverse effects were reported

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

**Doravirine:**

Effects on fertility	: Test Type: Fertility Species: Rat, male and female Fertility: NOAEL: 450 mg/kg body weight Result: No effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 450 mg/kg body weight Result: No adverse effects

## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
17.0	2025/11/20	58382-00030	2025/04/14
			Date of first issue: 2015/02/16

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 300 mg/kg body weight  
Result: No adverse effects

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Doravirine:**

Species : Rat  
NOAEL : 450 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL :  $> 450$  mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL :  $> 1,000$  mg/kg

## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

Application Route	: Oral
Exposure time	: 9 Months
Remarks	: No significant adverse effects were reported

**Magnesium stearate:**

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Doravirine:**

Ingestion	: Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression
-----------	--

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 ( <i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

**Doravirine:**

Toxicity to daphnia and other aquatic invertebrates	: EC50 ( <i>Americamysis</i> ): 9.1 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	: EC50 ( <i>Pseudokirchneriella subcapitata</i> (green algae)): > 5.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility  NOEC ( <i>Pseudokirchneriella subcapitata</i> (green algae)): 5.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC ( <i>Pimephales promelas</i> (fathead minnow)): 1 mg/l Exposure time: 32 d

## Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
17.0	2025/11/20	58382-00030	2025/04/14
			Date of first issue: 2015/02/16

		Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.38 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
<b>Magnesium stearate:</b>		
Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility
		NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

---

**Persistence and degradability****Components:****Cellulose:**

Biodegradability	: Result: Readily biodegradable.
------------------	----------------------------------

**Doravirine:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 2 % Exposure time: 28 d
------------------	--

**Magnesium stearate:**

Biodegradability	: Result: Not biodegradable Remarks: Based on data from similar materials
------------------	--

**Bioaccumulative potential****Components:****Doravirine:**

Partition coefficient: n-octanol/water	: log Pow: 2.08
--	-----------------

**Magnesium stearate:**

Partition coefficient: n-octanol/water	: log Pow: > 4
--	----------------

**Mobility in soil****Components:****Doravirine:**

Distribution among environmental compartments	: log Koc: 2.86
---	-----------------

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

---

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	: Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**Doravirine Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2025/04/14
17.0	2025/11/20	58382-00030	Date of first issue: 2015/02/16

---

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

**IATA-DGR**

Not regulated as a dangerous good

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

**IMDG-Code**

Not regulated as a dangerous good

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

**Special precautions for user**

Not applicable

**15. REGULATORY INFORMATION****Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

## Doravirine Formulation

Version 17.0      Revision Date: 2025/11/20      SDS Number: 58382-00030      Date of last issue: 2025/04/14  
Date of first issue: 2015/02/16

**Chemical Substance Control Law**

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

**Substances Prevented From Impairment of Health**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

**Substances Subject to be Notified Names**

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	$\geq 1$ - $< 10$	-

**Substances Subject to be Indicated Names**

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

Chemical name	Remarks
Magnesium stearate	-

**Skin and Eye Damage Substances (ISHL MO Art. 594-2)**

Not applicable

**Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)**

Not applicable

**Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

**Ordinance on Prevention of Lead Poisoning**

Not applicable

**Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

**Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

**Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

**Poisonous and Deleterious Substances Control Law**

Not applicable

## Doravirine Formulation

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

**Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

**High Pressure Gas Safety Act**

Not applicable

**Explosive Control Law**

Not applicable

**Vessel Safety Law**

Not regulated as a dangerous good

**Aviation Law**

Not regulated as a dangerous good

**Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

**Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

**Waste Disposal and Public Cleansing Law**

Industrial waste

**The components of this product are reported in the following inventories:**

AICS : not determined

CA. DSL : not determined

IECSC : not determined

---

**16. OTHER INFORMATION**

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

**Doravirine Formulation**

Version 17.0	Revision Date: 2025/11/20	SDS Number: 58382-00030	Date of last issue: 2025/04/14 Date of first issue: 2015/02/16
-----------------	------------------------------	----------------------------	---

---

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN